more_reports

New Alzheimer's Drugs Are Changing Brain Scans. This Company Is Preparing for What Comes Next

  ()
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is developing dedicated brain PET imaging clinics as new Alzheimer's treatments introduce follow-up scans and Medicare removes its once-per-lifetime restriction.
Tags: Medical DevicesLife Sciences Tools & Diagnostics

Pharma Co. Raises 2026 Guidance Amid Pancreatic Rival Pressure

  ()
Novocure Ltd. (NVCR:NASDAQ) reported record Q3 2026 revenue of US$193M, raised full-year guidance, and secured Japan approval for Optune Pax despite competition from KRAS inhibitors in pancreatic cancer.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Draws Split Analyst Ratings as RNA Pipeline Faces Clinical Tests

  ()
Sarepta Therapeutics Inc. (SRPT:NASDAQ) faces sharply divided analyst views, with H.C. Wainwright's US$5 Sell target contrasting with Wedbush's US$35 Buy target. Recent DM1 data, ELEVIDYS sales and upcoming results remain in focus.
Tags: Biotechnology / Pharmaceuticals

Virtual Care Platform Grows US Visits 56%, Eyes Record Quarter

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) completed 53,348 patient visits in the third quarter as U.S. visits jumped 56%, and the company expects record quarterly revenue. Find out why one analyst sees the AI telehealth company gaining meaningful traction in the U.S.
Tags: Artificial IntelligenceHealthcare ServicesLife Sciences Tools & DiagnosticsTechnology

Diabetes Cell Therapy Merger Nears Close Ahead of Q1 2027 First Patient Dosing

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) is nearing its proposed merger with Seraxis to form BetaNova, a type 1 diabetes cell therapy company that plans to dose its first patient in Q1 2027. Find out why one analyst sees blockbuster potential in the combined pipeline.
Tags: Biotechnology / PharmaceuticalsMedical Devices

MindBio Therapeutics Advances Voice AI Kiosk for Intoxication Detection Toward Commercial Pilot

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:FSE) completes next-generation Edge AI kiosk manufacture, advancing software validation for first commercial pilot in workplace safety screening.
Tags: Life Sciences Tools & Diagnostics

NervGen Kicks Off Pivotal Phase 3 Test of NVG-291 in Chronic Spinal Cord Injury

  ()
NervGen Pharma Corp. (NGEN:NASDAQ) has dosed the first patient in its pivotal Phase 3 trial of NVG-291 in chronic spinal cord injury, with topline data expected in the first half of 2028. Find out why one newsletter writer says investors may face a long wait.
Tags: Biotechnology / Pharmaceuticals

AI Cancer Drug Developer Secures Exclusive Rights in Expanded Brain Tumor Research Agreement

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) expanded its AI-powered drug discovery agreement, securing exclusive rights to a defined ATR inhibitor profile and additional optimization work at no extra cost.
Tags: Life Sciences Tools & DiagnosticsMedical DevicesArtificial Intelligence

The FDA Clarified Its Rules for Medical AI. This Stock Could Be on the Right Side of Them

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) continues to evolve its physician-led healthcare platform as revised FDA guidance, new state healthcare AI laws, and rising U.S. patient volumes reshape the regulatory and commercial environment.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Nvidia Commits US$1B to American Science Push in Tech, Energy, and Healthcare

  ()
Nvidia Corporation (NVDA:NASDAQ) announced commitments valued at US$1 billion over five years to advance U.S. scientific research and development, including quantum computing, healthcare and energy security, building on its partnerships with national laboratories and the Department of Energy.
Tags: Alternative EnergyTechnologyHealthcare Services

Solving a 10,000-Pound Problem: This Company Aims to Reinvent the Brain Scan

  ()
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is preparing to open its first dedicated brain PET imaging clinic as new Alzheimer's treatments drive demand for earlier, specialized imaging.
Tags: Medical DevicesLife Sciences Tools & Diagnostics

Can AI Find the Right Cancer Drug for the Right Patient? This Collaboration Is Putting It to Work

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) partners with Celvion on AI-driven precision strategies for its ATR inhibitor.
Tags: Biotechnology / Pharmaceuticals

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics, with a type 1 diabetes cell therapy trial planned for early 2027. Find out why one analyst says Sernova found the right partner.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / PharmaceuticalsMedical DevicesHealthcare Services

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response

  ()
Nektar Therapeutics (NKTR:NASDAQ) reports durable Phase 2b responses for rezpegaldesleukin in eczema and alopecia areata, as the Treg-targeted drug advances toward Phase 3.
Tags: Biotechnology / Pharmaceuticals

Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye

  ()
Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announces intent to submit Formal Dispute Resolution Request appealing March 2026 CRL for reproxalap in dry eye disease. Here is a plain-English guide to the FDA appeal process for investors.
Tags: Biotechnology / Pharmaceuticals

Satellos Targets Untapped FSHD Market With FDA-Cleared IND for Phase 2 Trial

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) received FDA clearance of its IND application for a planned Phase 2 study of forazapadin in FSHD; US$5M non-dilutive funding and quotes highlight regeneration potential where no therapies exist.
Tags: Biotechnology / Pharmaceuticals

Biotech and Life Sciences Stock News

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. Andre Uddin, Research Capital Corporation


"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com


"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com


"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. Andre Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. Andre Uddin, Research Capital Corporation


"AGN's current valuation is favorable from a risk-reward standpoint."

–Dr. Andre Uddin, Research Capital Corporation


Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment

  ()
Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) receives FDA alignment to continue its Phase 2 RP-A501 trial for Danon disease, with nine additional patients expected to be treated by mid-2027.
Tags: Biotechnology / Pharmaceuticals

Fennec Pharmaceuticals Reports PEDMARK Data Showing Reduced Hearing Loss in Japanese Study

  ()
Fennec Pharmaceuticals Inc. (FENC:NASDAQ;FRX:TSE) reports Phase 2 STS-J01 results for PEDMARK in Japan, with ASHA-defined hearing loss in 24% of patients versus a 56.4% benchmark.
Tags: Biotechnology / Pharmaceuticals

Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302

  ()
Coya Therapeutics reaches 100-patient enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, with full enrollment and topline data expected soon. Learn key catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Medicus's Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drug

Contributed Opinion
  ()
Mike Sheikh shares his thoughts on Medicus Pharma Ltd. (MDCX:NASDAQ) after its recent deal with Pfizer Inc. (PFE:NYSE).
Tags: Biotechnology / Pharmaceuticals

Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant

  ()
Coya Therapeutics Inc. (COYA:NASDAQ) enrolls its 100th participant in the Phase 2/3 ALSTARS trial of COYA 302 for ALS, with topline data expected in early Q2 2027.
Tags: Biotechnology / Pharmaceuticals